Investor Presentation and Revised Revenue Guidance
Renalytix plc has released revised forward revenue guidance, anticipating $8.4 million in FY26. The company projects revenue of $19.0 million in FY27 and $42.0 million in FY28, reflecting the expected positive impact from their collaboration with Tempus AI, Inc. This updates the previous outlook provided in the Half Year Report on March 18, 2025, which estimated $8.5 million for FY26 and $17.5 million for FY27. The Board is evaluating the long-term benefits of the Tempus collaboration and plans to provide further updates on revenue guidance as implementation progresses.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 23 September 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that an updated corporate presentation will be available today for download from the Company's website at https://investors.renalytix.com/presentations/.
The corporate presentation includes revised forward guidance on the Company's expected revenue: $8.4m in FY26, $19.0m in FY27 and $42.0m in FY28 with the later years of FY27 and FY28 reflecting the anticipated positive revenue impact from Renalytix's recently announced collaboration agreement with Tempus AI, Inc. (Nasdaq: TEM) ("Tempus"). This revenue guidance compares to a prior outlook through FY27 calling for $8.5m in FY26, and $17.5m for FY27 as provided in the Company's Half Year Report on 18 March 2025.
The Board of Directors are currently considering the long-term positive impact of the Tempus collaboration and the Company will provide further updates regarding forward revenue guidance as appropriate, as the two parties execute implementation into hospital systems and other healthcare providers.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.